A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
PurposeGC1118 is a novel antibody targeting epidermal growth factor receptor (EGFR) with enhanced blocking activity against both low- and high-affinity EGFR ligands. A phase 1b/2a study was conducted to determine a recommended phase 2 dose (RP2D) of GC1118 in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) (phase 1b) and to assess the safety and efficacy of GC1118 plus FOLFIRI as a second-line therapy for recurrent/metastatic colorectal cancer (CRC) (phase 2a).Materials and MethodsPhase 1b was designed as a standard 3+3 dose-escalation study with a starting dose of GC1118 (3 mg/kg/week) in combination with biweekly FOLFIRI (irinotecan 180 mg/m<sup>2</sup>; leucovorin 400 mg/m<sup>2</sup>; 5-fluorouracil 400 mg/m<sup>2</sup> bolus and 2,400 mg/m<sup>2</sup> infusion over 46 hours) in patients with solid tumors refractory to standard treatments. The subsequent phase 2a part was conducted with objective response rate (ORR) as a primary endpoint. Patients with KRAS/NRAS/BRAF wild-type, EGFR-positive, recurrent/metastatic CRC resistant to the first-line treatment were enrolled in the phase 2a study.ResultsRP2D of GC1118 was determined to be 3 mg/kg/wk in the phase 1b study (n=7). Common adverse drug reactions (ADRs) observed in the phase 2a study (n=24) were acneiform rash (95.8%), dry skin (66.7%), paronychia (58.3%), and stomatitis (50.0%). The most common ADR of ≥ grade 3 was neutropenia (33.3%). ORR was 42.5% (95% confidence interval [CI], 23.5 to 62.0), and median progression-free survival was 6.7 months (95% CI, 4.0-8.0).ConclusionGC1118 administered weekly at 3 mg/kg in combination with FOLFIRI appears as an effective and safe treatment option in recurrent/metastatic CRC.
Abstract
PurposeGC1118 is a novel antibody targeting epidermal growth factor receptor (EGFR) with enhanced blocking activity against both low- and high-affinity EGFR ligands. A phase 1b/2a study was conducted to determine a recommended phase 2 dose (RP2D) of GC1118 in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) (phase 1b) and to assess the safety and efficacy of GC1118 plus FOLFIRI as a second-line therapy for recurrent/metastatic colorectal cancer (CRC) (phase 2a).Materials and MethodsPhase 1b was designed as a standard 3+3 dose-escalation study with a starting dose of GC1118 (3 mg/kg/week) in combination with biweekly FOLFIRI (irinotecan 180 mg/m<sup>2</sup>; leucovorin 400 mg/m<sup>2</sup>; 5-fluorouracil 400 mg/m<sup>2</sup> bolus and 2,400 mg/m<sup>2</sup> infusion over 46 hours) in patients with solid tumors refractory to standard treatments. The subsequent phase 2a part was conducted with objective response rate (ORR) as a primary endpoint. Patients with KRAS/NRAS/BRAF wild-type, EGFR-positive, recurrent/metastatic CRC resistant to the first-line treatment were enrolled in the phase 2a study.ResultsRP2D of GC1118 was determined to be 3 mg/kg/wk in the phase 1b study (n=7). Common adverse drug reactions (ADRs) observed in the phase 2a study (n=24) were acneiform rash (95.8%), dry skin (66.7%), paronychia (58.3%), and stomatitis (50.0%). The most common ADR of ≥ grade 3 was neutropenia (33.3%). ORR was 42.5% (95% confidence interval [CI], 23.5 to 62.0), and median progression-free survival was 6.7 months (95% CI, 4.0-8.0).ConclusionGC1118 administered weekly at 3 mg/kg in combination with FOLFIRI appears as an effective and safe treatment option in recurrent/metastatic CRC.
참고문헌 (18)
- Baidoun F, "Colorectal cancer epidemiology : recent trends and impact on outcomes", Curr Drug Targets, 22, pp.998~1009 (2021)
- Ferlay J, "Cancer statistics for the year 2020 : an overview", Int J Cancer, 149, pp.778~789 (2021)
- Biller LH, "Diagnosis and treatment of metastatic colorectal cancer : a review", JAMA, 325, pp.669~685 (2021)
- Martinelli E, "Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy", Clin Exp Immunol, 158, pp.1~9 (2009)
- Yewale C, "Epidermal growth factor receptor targeting in cancer : a review of trends and strategies", Biomaterials, 34, pp.8690~8707 (2013)
- Messersmith WA, "Targeting EGFR in colorectal cancer", N Engl J Med, 359, pp.1834~1836 (2008)
- Bronte G, "New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer : do all roads lead to RAS?", Oncotarget, 6, pp.24780~24796 (2015)
- Zhou J, "Resistance to anti-EGFR therapies in metastatic colorectal cancer : underlying mechanisms and reversal strategies", J Exp Clin Cancer Res, 40, pp.328~ (2021)
- Lim Y, "GC1118, an Anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands", Mol Cancer Ther, 15, pp.251~263 (2016)
- Park WS, "Use of a target-mediated drug disposition model to predict the human pharmacokinetics and target occupancy of GC1118, an antiepidermal growth factor receptor antibody", Basic Clin Pharmacol Toxicol, 120, pp.243~249 (2017)
- Park JE, "GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer", Gastric Cancer, 22, pp.932~940 (2019)
- Lee HW, "Promising therapeutic efficacy of GC1118, an anti-EGFR antibody, against KRAS mutation-driven colorectal cancer patientderived xenografts", Int J Mol Sci, 20, pp.5894~ (2019)
- Lee K, "Therapeutic efficacy of GC1118, a novel anti-EGFR antibody, against glioblastoma with high EGFR amplification in patient-derived xenografts", Cancers(Basel), 12, pp.3210~ (2020)
- Oh DY, "A firstin-human phase I study of GC1118, a novel anti-epidermal growth factor receptor antibody, in patients with advanced solid tumors", Oncologist, 24, pp.1037-e636~ (2019)
- Simon R, "Optimal two-stage designs for phase II clinical trials", Control Clin Trials, 10, pp.1~10 (1989)
- Peeters M, "Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan(FOLFIRI)compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer", J Clin Oncol, 28, pp.4706~4713 (2010)
- Hecht JR, "SPIRITT : a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer", Clin Colorectal Cancer, 14, pp.72~80 (2015)
- Chung TK, "A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors", Clin Transl Sci, 14, pp.990~1001 (2021)